Double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis.

about

Double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis.

Item

http://www.wikidata.org/entity/Q50880137

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Double benefit of long-acting ...... megaly and ulcerative colitis.

@en

Double benefit of long-acting ...... megaly and ulcerative colitis.

@nl

type

Item

label

Double benefit of long-acting ...... megaly and ulcerative colitis.

@en

Double benefit of long-acting ...... megaly and ulcerative colitis.

@nl

prefLabel

Double benefit of long-acting ...... megaly and ulcerative colitis.

@en

Double benefit of long-acting ...... megaly and ulcerative colitis.

@nl

P1476

Double benefit of long-acting ...... megaly and ulcerative colitis.

@en

P2093

B Canbaz

http://www.w3.org/2001/XMLSchema#string

F Akyuz

http://www.w3.org/2001/XMLSchema#string

G Y Yalın

http://www.w3.org/2001/XMLSchema#string

S C Dogansen

http://www.w3.org/2001/XMLSchema#string

S Tanrıkulu

http://www.w3.org/2001/XMLSchema#string

S Yarman

http://www.w3.org/2001/XMLSchema#string

P2860

Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Somatostatin analogues suppress the inflammatory reaction in vivo

Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

Systemic complications of acromegaly: epidemiology, pathogenesis, and management.

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.

Medical progress: Acromegaly.

P304

559-562

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCPT.12412

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27380906

http://www.w3.org/2001/XMLSchema#string